Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.96 |
| ▸ | ACHE | P22303 | 1/20 | 0.96 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL4965 | 0.98 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2352524 | 0.98 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL29669592 | 0.98 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL31152020 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7044227 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2454001 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL1507586 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7044230 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL31048830 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7849418 | 0.96 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1460074-A1 | Substituted amino alkyl compounds | CELL THERAPEUTICS, INC. (US) | 2004-09-22 | — | — | EP | claimed |
| EP-0719267-B1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 2002-07-31 | — | — | EP | claimed |
| US-6121270-A | N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI | CELL THERAPEUTICS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| US-5780476-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS | CELL THERAPEUTICS, INC. (US) | 1998-07-14 | — | — | US | claimed |
| US-5770595-A | Oxime substituted therapeutic compounds | CELL THERAPEUTICS, INC. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0719267-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| EP-0669825-A4 | HYDROXYL-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-03 | — | — | EP | claimed |
| EP-0719267-A4 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 1996-02-16 | — | — | EP | claimed |
| EP-0623133-A4 | SUBSTITUTED AMINO ALKYL COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1995-10-11 | — | — | EP | claimed |
| EP-0669825-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-09-06 | — | — | EP | claimed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | claimed |
| EP-0623133-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-11-09 | — | — | EP | claimed |
| WO-1994024133-A1 | RING-SUBSTITUTED CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994016704-A1 | OXIME-SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1994015605-A1 | ACETAL OR KETAL SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| EP-0260127-A2 | Xanthine derivatives, their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-03-16 | — | — | EP | claimed |
| EP-1460074-A1 | Substituted amino alkyl compounds | CELL THERAPEUTICS, INC. (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6693105-B1 | USING XANTHINYL DERIVATIVES TO REDUCE TREATMENT INDUCED TOXICITY; INHIBITING CELLULAR SIGNALING THROUGH SECOND MESSENGER PATHWAY; REDUCING CELLULAR LEVEL OF NONARACHI-DONATE PHOSPHATIDIC ACID AND DIACYLGLYCEROL | CELL THERAPEUTICS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030207901-A1 | Hydroxyl-containing compounds | CELL THERAPEUTICS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-0719267-B1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-0389282-B1 | Xanthinederivatives, process for their preparation and their pharmaceutical use | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 2002-02-20 | — | — | EP | disclosed |
| EP-1120417-A2 | Xanthine derivatives for the treatment of cerebrovascular disorders | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6180791-B1 | REDUCING NITRO GROUPS TO FORM AMINO GROUPS | BEECHAM GROUP P.L.C. (GB) | 2001-01-30 | — | — | US | disclosed |
| US-6133274-A | TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS | CELL THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6121270-A | N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI | CELL THERAPEUTICS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6103730-A | Amine substituted compounds | CELL THERAPEUTICS, INC. (US) | 2000-08-15 | — | — | US | disclosed |
| US-6100271-A | Therapeutic compounds containing xanthinyl | CELL THERAPEUTICS, INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0563168-B1 | XANTHINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 2000-07-05 | — | — | EP | disclosed |
| US-6043250-A | Methods for using therapeutic compounds containing xanthinyl | CELL THERAPEUTICS, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5981535-A | FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-09 | — | — | US | disclosed |
| US-5889011-A | THERAPY FOR SEPSIS; ORGAN TOXICITY, ALOPECIA, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | CELL THERAPEUTICS, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5866576-A | COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. | CELL THERAPEUTICS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5837703-A | AUTOIMMUNE DISEASES, ARTHRITIS, CANCER, LEUKEMIA, MULTIPLE SCLEROSIS; ANTITUMOR AGENTS | CELL THERAPEUTICS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5817662-A | THERAPY FOR SEPTIC SHOCK, ALOPECIA; INFLAMMATION;AUTOIMMUNE DISEASES | CELL THERAPEUTICS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5807861-A | Amine substituted xanthinyl compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5807862-A | Therapeutic compounds containing pyrimidinyl moieties | CELL THERAPEUTICS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5804584-A | USEFUL IN TREATING INDIVIDUALS HAVING A DISEASE OR TREATMENT-INDUCED TOXICITY, MEDIATED BY SECOND MESSENGER ACTIVITY | CELL THERAPEUTICS, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5801182-A | Amine substituted compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5780476-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS | CELL THERAPEUTICS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5777115-A | DISEASES MEDIATED BY INTRACELLULAR SIGNALING | CELL THERAPEUTICS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5770595-A | Oxime substituted therapeutic compounds | CELL THERAPEUTICS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | disclosed |
| EP-0746557-A4 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS INC (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0746557-A1 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0719267-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0697873-A4 | — | — | 1996-04-03 | — | — | EP | disclosed |
| EP-0669825-A4 | HYDROXYL-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0697873-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0719267-A4 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 1996-02-16 | — | — | EP | disclosed |
| US-5470878-A | Cell signaling inhibitors | CELL THERAPEUTICS, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0623133-A4 | SUBSTITUTED AMINO ALKYL COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1995-10-11 | — | — | EP | disclosed |
| EP-0669825-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995022546-A1 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS, INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5409934-A | Antiallergens | BEECHAM GROUP P.L.C. (GB) | 1995-04-25 | — | — | US | disclosed |
| EP-0641344-A1 | 8-SUBSTITUTED ANTHINES AS PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | disclosed |
| EP-0623133-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994024133-A1 | RING-SUBSTITUTED CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0369744-B1 | Xanthine derivatives, process for their preparation and pharmaceutical compositions | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1994-09-21 | — | — | EP | disclosed |
| WO-1994016704-A1 | OXIME-SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994015606-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015605-A1 | ACETAL OR KETAL SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5321029-A | Vascular and skin disorders; bronchodilator | BEECHAM-WUELFING GMBH & CO.K.G. (DE) | 1994-06-14 | — | — | US | disclosed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1993023401-A1 | 8-SUBSTITUTED ANTHINES AS PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1993-11-25 | — | — | WO | disclosed |
| EP-0558659-A4 | TNF INHIBITORS | — | 1993-10-20 | — | — | EP | disclosed |
| EP-0563168-A1 | XANTHINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1993-10-06 | — | — | EP | disclosed |
| EP-0558659-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1993016699-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
| EP-0550570-A1 | XANTHINE DERIVATIVES | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0550559-A1 | XANTHINES | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992011260-A1 | XANTHINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-07-09 | — | — | WO | disclosed |
| WO-1992009203-A1 | TNF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992005175-A1 | XANTHINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
| WO-1992005176-A1 | XANTHINES | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | disclosed |
| EP-0369744-A2 | Xanthine derivatives, process for their preparation and pharmaceutical compositions | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0260127-A2 | Xanthine derivatives, their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-03-16 | — | — | EP | disclosed |
| EP-0260127-A2 | Xanthine derivatives, their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207901-A1 | Hydroxyl-containing compounds | HCCS, CNR1, WNT1 | GDA 2283/4885ACHE 3567/4885ABL1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.